

#17/K.T. III TECH CENTER 160 OFFICER 160

In re application of: LI et al.

Application Serial No.: 09/348,815

Art Unit: 1635

Filed: July 8, 1999

Examiner: Zara, J.

For: Connective Tissue Growth Factor-2

Attorney Docket No.: PF126P1D1

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321(b)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The undersigned attorney of record hereby represents that Human Genome Sciences, Inc. (hereinafter, the "Assignee") is owner of the entire right, title and interest in and to the above-identified application by virtue of assignments which were recorded on April 22, 1996, at Reel 7937, Frame 0374 in Application Serial No. 08/459,101, filed July 8, 1999.

The Assignee hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of U.S. Patent No. 5,945,300, which issued on August 31, 1999, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to any such patent granted on the above-identified application shall be the same as the legal title to U.S Patent No. 5,945,300.

The Assignee further agrees that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantee, its successors, and assigns.

The Assignee does not disclaim any terminal part of the patent granted on the above-identified application prior to the respective expiration date of the full statutory term of U.S. Patent No. 5,945,300 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the